- Home
- NHIC vs MNPR Comparison
NHIC vs MNPR Comparison
Compare NHIC & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NHIC
- MNPR
- Stock Information
- Founded
- NHIC 2024
- MNPR 2014
- Country
- NHIC United States
- MNPR United States
- Employees
- NHIC N/A
- MNPR N/A
- Industry
- NHIC
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- NHIC
- MNPR Health Care
- Exchange
- NHIC NYSE
- MNPR Nasdaq
- Market Cap
- NHIC 276.7M
- MNPR 249.5M
- IPO Year
- NHIC 2025
- MNPR 2019
- Fundamental
- Price
- NHIC $10.04
- MNPR $30.01
- Analyst Decision
- NHIC
- MNPR Strong Buy
- Analyst Count
- NHIC 0
- MNPR 5
- Target Price
- NHIC N/A
- MNPR $59.50
- AVG Volume (30 Days)
- NHIC 3.3K
- MNPR 20.8K
- Earning Date
- NHIC 01-01-0001
- MNPR 05-13-2025
- Dividend Yield
- NHIC N/A
- MNPR N/A
- EPS Growth
- NHIC N/A
- MNPR N/A
- EPS
- NHIC N/A
- MNPR N/A
- Revenue
- NHIC N/A
- MNPR N/A
- Revenue This Year
- NHIC N/A
- MNPR N/A
- Revenue Next Year
- NHIC N/A
- MNPR N/A
- P/E Ratio
- NHIC N/A
- MNPR N/A
- Revenue Growth
- NHIC N/A
- MNPR N/A
- 52 Week Low
- NHIC $10.02
- MNPR $1.72
- 52 Week High
- NHIC $10.22
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- NHIC N/A
- MNPR 34.22
- Support Level
- NHIC N/A
- MNPR $28.40
- Resistance Level
- NHIC N/A
- MNPR $36.82
- Average True Range (ATR)
- NHIC 0.00
- MNPR 3.29
- MACD
- NHIC 0.00
- MNPR -0.79
- Stochastic Oscillator
- NHIC 0.00
- MNPR 13.50
About NHIC NEWHOLD INVESTMENT CORP III
NewHold Investment Corp III is a blank check company.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.